Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society
- Presentations will highlight data analyses across multiple disease states -
- New, nonclinical data indicates potential for suprachoroidal administration of gene-based therapies -
ALPHARETTA, Ga., February 14, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple oral presentations will be given at the 42nd Annual Macula Society Meeting being held February 13-16, 2019 in Bonita Springs, Florida. The four scientific presentations will review clinical and nonclinical data analyses of Clearside programs in multiple disease states, including macular edema associated with uveitis and diabetic macular edema, as well as gene therapy.
Following are the presentation details:
Presentation:
Dr. Charles Wykoff, Physician, Surgeon, Co-Director of Greater Houston Retina Research Center, & Clinical Assistant Professor of Ophthalmology, Retina Consultants of Houston will present the results of the Phase 2 TYBEE trial in diabetic macular edema.
Title: Suprachoroidal CLS-TA Plus Aflibercept Compared to Aflibercept Monotherapy for Diabetic Macular Edema: Results of the Randomized Phase 2 TYBEE Trial
Date: Friday, February 15, 2019
Time: 11:39 AM – 11:48 AM
Location: Main Ballroom
Presentation:
Dr. Szilard Kiss, Director of Clinical Research, Associate Professor of Ophthalmology, Weill Cornell Medical College will present nonclinical data providing preliminary evidence of the potential for suprachoroidal administration of gene-based therapies.
Title: A new approach to ocular gene therapy: Evaluation of suprachoroidal administration of non-viral DNA nanoparticles in a rabbit model
Date: Saturday, February 16, 2019
Time: 7:39 AM – 7:48 AM
Location: Main Ballroom
Presentation:
Dr. Seenu Hariprasad, Chief, Vitreoretinal Service, University of Chicago will present a combined analysis on the results from the AZALEA, DOGWOOD, and PEACHTREE studies in macular edema.
Title: Suprachoroidally Injected CLS-TA Results in Rapid and Sustained
Resolution of Macular Edema in a Majority of Uveitis Patients: Results of
the AZALEA, DOGWOOD, and PEACHTREE Studies
Date: Saturday, February 16, 2019
Time: 12:52 PM - 1:01 PM
Location: Main Ballroom
Presentation:
Dr. Steven Yeh, Associate Professor, Emory Eye Center will review results of XIPERE from the Phase 3 PEACHTREE study.
Title: Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in
Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study
Date: Saturday, February 16, 2019
Time: 1:01 PM - 1:10 PM
Location: Main Ballroom
The presentations will be available on Tuesday, February 19, 2019 on Clearside’s website in the Science section under Programs: (http://www.clearsidebio.com/programs.htm#SCIENCE).
About XIPERE
XIPERE (triamcinolone acetonide suprachoroidal injectable suspension), formerly known as CLS-TA, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via suprachoroidal injection for the treatment of macular edema associated with uveitis. Clearside’spatented technology is designed to deliver drug to the suprachoroidal space located between the choroid and the outer protective layer of the eye, known as the sclera. Suprachoroidal injection enables the rapid and adequate dispersion of medicine to the back of the eye offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye, thus potentially providing advantageous and sustained efficacy with a
favorable safety profile. A New Drug Application (“NDA”) was sub
and Drug Administrationecember(“FDA”)2018 forin XIPERE,D and, if approved, XIPERE will be the first therapy indicated for macular edema associated with uveitis.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases.
Clearside’s proprietary suprachoroidal treatment approach of to the back of the eye where sight-threatening disease often occurs. The company’s unique platform for eye disease treatments is inherently flexible and intended to work with
established medicines, new formulations of medicines, as well as future innovations such as gene therapy. Clearside is headquartered in Alpharetta, GA. For more information, please visit http://www.clearsidebio.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as
“believe”, “expect”, “may”, “plan”, “potential”, “will”, a based on Clearside’s current beliefs and expectations-lookingstatements.These forwa include expectations regarding the clinical development candidates, the potential attributes and benefits andof Clears the potential approval and commercialization of XIPERE in the United States. These
statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of
clinical trials, Clearside’s reliance on third parties over control, and other risks and uncertainties that are rtdescribe on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and
Exchange Commission on(“SEC”)March16, 2018, Clearside’s Quarterly Repor
Form 10-Q for the quarter ended September 30, 2018, filed with the SEC on November
8, 2018, and Clearside’s other Periodic ReportsSEC.Anyforwardfiled-lookingwith the statements speak only as of the date of this press release and are based on information
available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Contacts:
Jenny Kobin (919) 423-4299 Remy Bernarda (415) 203-6386 ir@clearsidebio.com
Source: Clearside Biomedical, Inc.